Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of ERY-ASP in newly diagnosed Acute-lymphoblastic-leukaemia (ALL)

Next Previous
Trial Profile

Phase I study of ERY-ASP in newly diagnosed Acute-lymphoblastic-leukaemia (ALL)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 24 Jun 2018 According to a ERYtech Pharma media release, the company has ceased the development of Eryaspase in Acute Lymphoblastic Leukemia (ALL)including the withdrawal of its European MAA, based on recent feedback from the regulatory agencies in Europe and the United States, which states that, the company would require an additional investment in order to seek regulatory approval of eryaspase for the treatment of ALL.
  • 24 Jun 2018 Status changed from recruiting to discontinued, according to a ERYtech Pharma media release.
  • 14 May 2018 According to an ERYtech Pharma media release, full results were presented at the annual meeting of the American Association for Cancer Research (AACR).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top